Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2019 | Kidney cancer: post-surgery sorafenib

Tim Eisen • 28 Sep 2019
ESMO 2019
Genitourinary Cancer Kidney Cancer Sorafenib
SORCE

Tim Eisen, MBBChir, PhD, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK, describes the rationale and methodology behind the SORCE trial (NCT00492258) and what have we learned at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.

More from Tim Eisen

3:04
Kidney cancer: minimizing toxicities and hassle in adjuvant therapy
Tim Eisen • 29 Sep 2019

Related Videos

4:05
Evaluating triplet therapy in metastatic hormone sensitive prostate cancer
Nick James • 24 Apr 2024
10:42
Management of prostate cancer from the patient perspective
David Matheson • 11 Apr 2024
2:26
Prognostic factors of renal cell cancer in elderly patients
Teemu Murtola • 9 Apr 2024
2:44
The effect of hypoxia on lipid metabolism and prostate cancer tumor growth
Teemu Murtola • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals